Viktig informasjon i saken hentes i sanntid direkte fra EPO sitt register (European Patent Register), slik at du enkelt og raskt får oversikt i saken.
Beskrivelse Verdi
Saken / databasen er sist oppdatert info  
Tittel DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
Status
Hovedstatus
Detaljstatus
I kraft info EP patent gjort gjeldende i Norge EP patent besluttet gjeldende i Norge
Patentnummer NO/EP3366293
Europeisk (EP) publiserings nummer EP3366293
EP levert
EP søknadsnummer 17208408.9
EP meddelt
Prioritet Ingen
Sakstype Europeisk
Løpedag
Utløpsdato
Allment tilgjengelig
Validert i Norge
Innehaver Deciphera Pharmaceuticals, LLC (US)
Oppfinner FLYNN, Daniel L. (US) .... se mer/flere nedenfor
Fullmektig ZACCO NORWAY AS (NO)
Supplerende beskyttelsessertifikat(SPC) 2022010  
Lenke til European patent Register Informasjon i saken, dokumenter og patentfamilie
Patentfamilie Se i Espacenet

EPO translation logo


Se forsidefigur og sammendrag i Espacenet

T3

Beskrivelse

Krav

Patentkrav1. En forbindelse for bruk i behandling av en sykdom forårsaket av kinase-aktiviteten av c-KIT, onkogene former derav, eller polymorfe derav, hos en pasient med behov for dette, hvor sykdommen er valgt fra gruppen bestående av gastrointestinale stromale tumorer, ovarier kreft, melanom, akutt myeloid leukemi, kimcelle tumorer av seminom eller dysgerminom, teratomer, mastocytose og mastcelleleukemi, omfattende å administrere til pasienten en terapeutisk effektiv mengde av en forbindelse valgt fra gruppen bestående av:1-(4-klor-3-(1-metyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)fenyl)-3-(3-cyanfenyl)urea, 1-(3-cyanfenyl)-3-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)urea, 1-(benzo[b]tiofen-3-yl)-3-(2-fluor-4-metyl-5-(1-metyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)fenyl)urea, 1-(benzo[b]tiofen-3-yl)-3-(2,4-difluor-5-(1-metyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)fenyl)urea, 1-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2,4-difluorfenyl)-3-(3-fluorfenyl)urea, 1-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2,4-difluorfenyl)-3-fenylurea, 1-(3-klorfenyl)-3-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2,4-difluorfenyl)urea, 1-(3-cyanfenyl)-3-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2,4-difluorfenyl)urea, 1-(benzo[b]tiofen-3-yl)-3-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2,4-difluorfenyl)urea,1-(5-(7-amino-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-4-klor-2-fluorfenyl)-3-(3-fluorfenyl)urea, 1-(5-(7-amino-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-4-klor-2-fluorfenyl)-3-fenylurea, 1-(4-klor-2-fluor-5-(1-isopropyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)fenyl)-3-fenylurea, 1-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-4-metylfenyl)-3-fenylurea, 1-[4-klor-5-(1-etyl-7-metylamino-2-okso-1,2-dihydro-[1,6]naftyridin-3-yl)-2-fluor-fenyl]-3-(3-fluor-fenyl)-urea, 1-[4-kloro-5-(1-etyl-7-metylamino-2-okso-1,2-dihydro-[1,6]naftyridin-3-yl)-2-fluor-fenyl]-3-(2-fluorfenyl)-urea, 1-(4-klor-3-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-fenylurea, 1-(4-klor-5-(1-etyl-7-(2-metoksyetylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-fenylurea, 1-(4-klor-5-(1-etyl-7-(2-metoksyetylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-(3-fluorfenyl)urea, 1-(4-klor-5-(7-(2-(dimetylamino)etylamino)-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-fenylurea, 1-(4-klor-5-(7-(3-(dimetylamino)propylamino)-1-etyl-2okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-fenylurea, 1-(4-brom-5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-fenylurea, 1-(benzo[b]tiofen-3-yl)-3-(4-klor-5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)urea, 1-(4-klor-3-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)fenyl)-3-fenylurea, 1-(4-klor-5-(1-etyl-7-(2-metoksyetylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-(4-fluorfenyl)urea, 1-(4-klor-5-(1-etyl)-7-(2-metoksyetylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-(2-fluorfenyl)urea, 1-(5-(1-etyl-7-(2-metoksyetylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2,4-difluorfenyl)-3-fenylurea, 1-(5-(1-etyl-7-(2-metoksyetylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-4-metylfenyl)-3-fenylurea, 1-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-4-metylfenyl)-3-(2-fluorfenyl)urea, 1-(4-klor-5-(1-etyl-7-(3-metoksypropylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-fenylurea,1-(2,4-difluor-5-(1-isopropyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)fenyl)-3-(3-fluorfenyl)urea, 1-(2-fluor-5-(1-isopropyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-4-metylfenyl)-3-(3-fluorfenyl)urea, 1-(4-klor-5-(1-etyl-2-okso-7-(tetrahydro-2H-pyran-4-ylamino)-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-fenylurea, (S)-1-(4-klor-5-(1-etyl-7-(1-metoksypropan-2-ylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-fenylurea, 1-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-4-metylfenyl)-3-(3-fluorfenyl)urea, 1-(5-(7-(syklopropylamino)-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-4-metylfenyl)-3-(3-fluorfenyl)urea, 1-(4-klor-5-(1-etyl-7-(1-metylpiperidin-4-ylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-fenylurea, 1-(4-klor-5)-(1-etyl-2-okso-7-(THF-3-ylamino)-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-fenylurea, 1-(4)-klor-5-(1-etyl-7-(2-(metylsulfonyl)etylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-fenylurea, 1-(4-klor-5-(1-etyl-7-(1-metylpyrrolidin-3-ylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-fenylurea, 1-(4-brom-5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-(3-fluorfenyl)urea, 1-(4-brom-5-(1-etyl-7-(2-metoksyetylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-fenylurea,1-(4-brom-5-(1-etyl-7-(2-(metylsulfonyl)etylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-fenylurea, 1-(5-(7-acetamido-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-4-brom-2-fluorfenyl)-3-fenylurea, 1-(5-(7-acetamido-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-4-klor-2-fluorfenyl)-3-fenylurea, 1-(4-klor-5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-(3-, 5-difluorfenyl)urea, 1-(4-brom-2-fluor-5-(1-metyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)fenyl)-3-fenylurea, 1-(5-(7amino-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-4-brom-2-fluorfenyl 3-fenylurea, 1-(5-(7-amino-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-4-metylfenyl)-3-(3-fluorfenyl)urea, 1-(benzo[b]tiofen-3-yl)-3-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-4-metylfenyl)urea, 1-(3,5-difluorfenyl)-3-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-4-metylfenyl)urea, 1-(2,5-difluorfenyl)-3-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-4-metylfenyl)urea, 1-(2,5-difluorfenyl)-3-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2,4-difluorfenyl)urea, 1-(3,5-difluorfenyl)-3-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2,4-difluorfenyl)urea, N-(3-(2-brom-4-fluor-5-(3-fenylureido)fenyl)-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)-2-cyanacetamid, N-(3-(2-klor-4-fluor-5-(3-fenylureido)fenyl)-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)-2-cyanacetamid,1-(5-(7-acetamido-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2,4-difluorfenyl)-3-fenylurea, N-(3-(2-klor-5-(3-(3,5-difluorfenyl)ureido)-4-fluorfenyl)-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)acetamid, 1-(4-klor-5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-(2,5-difluorfenyl)urea, 1-(3-kloro-5-fluorfenyl)-3-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-4-metylfenyl)urea, 3-(3-(2-klor-4-fluor-5-(3-fenylureido)fenyl)-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)-1,1-dimetylurea, 1-(4-klor-5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-(3-klor-5-fluorfenyl)urea, 1-(4-klor-5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-(3-fluor-5-metylfenyl)urea, metyl(3-(2-klor-4)-fluor-5-(3-fenylureido)fenyl)-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)karbamat, N-(3-(2-klor-4)-fluor-5-(3-fenylureido)fenyl)-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)-2-metoksyacetamid, 2-cyan-N-(3-(2,4-difluor-5-(3-fenylureido)fenyl)-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-7-yl) acetamid, 1-(4-cyan-5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-fenylurea, 1-(4-klor-2-fluor-5-(1-isopropyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)fenyl)-3-(3-fluorfenyl)urea, N-(1-etyl-3)-(4-fluor-5-(3-(3-fluorfenyl)ureido)-2-metylfenyl)-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)acetamid, 1-(4)-klor-5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-(3-((4-metylpiperazin-1-yl)metyl)fenyl)urea, N-(1-etyl-3-(4-fluor-2-metyl-5-(3-fenylureido)fenyl)-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)acetamid, N-(3-(2-klor-4-fluor-5-(3-fenylureido)fenyl)-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)-3-hydroksyazetidin-1-karboksamid, 1-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-4-metylfenyl)-3-(3-((4-metylpiperazin-1-yl)metyl)fenyl)urea, 1-(4-brom-5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6naftyridin-3-yl)-2-fluorfenyl)-3-(3-((4-metylpiperazin-1-yl)metyl)-fenyl)urea, (R)-N-(3-(2-klor-4-fluor-5-(3-fenylureido)fenyl)-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)-3-(dimetylamino)pyrrolidin-1-karboksamid, (S)-N-(3-(2-klor-4-fluor-5-(3-fenylureido)fenyl)-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)pyrrolidin-2-karboksamid, N-(3-(2-klor-4-fluor-5-(3-fenylureido)fenyl)-1-isopropyl-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)acetamid, 1-(4-klor-5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-(4-fluor-3-((4-metylpiperazin-1-yl)metyl)fenyl)urea, 1-(4-klor-5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-(3-fluor-5-((4-metylpiperazin-1-yl)metyl)fenyl)urea,1-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-4-metylfenyl)-3-(4-fluor-3-((4-metylpiperazin-1-yl)metyl)fenyl)urea, 1-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2,4-difluorfenyl)-3-(4-fluor-3-((4-metylpiperazin-1-yl)metyl)fenyl)urea, 1-(4-klor-5-(1)-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-(3-cyanfenyl)urea, 1-(4-klor)-5-(1-etyl-7-((3-morfolinopropyl)amino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-fenylurea, 1-(5-(7-amino-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-4-metylfenyl)-3-(4-fluor-3-((4-metylpiperazin-1-yl)metyl)fenyl)urea, 1-(4-klor-5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-(3-((dimetylamino)metyl)-4-fluorfenyl)urea, 1-(4-klor-5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-(4-fluor-3-(morfolinometyl)fenyl)urea, (S)-N-(3-(2-klor-4-fluor-5-(3-fenylureido)fenyl)-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)-3-(dimetylamino)pyrrolidin-1-karboksamid, 1-(4-klor-5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-(4-fluor-3-(pyrrolidin-1-ylmetyl)fenyl)urea, 3-(3-(2-klor-4-fluor-5-(3-(3-fluorfenyl)ureido)fenyl)-1-isopropyl-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)-1,1-dimetylurea, N-(3-(2-klor-4-fluor-5-(3-(3-fluorfenyl)ureido)fenyl)-1-isopropyl-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)acetamid, N-(1-etyl-3-(4-fluor-5-(3-(4-fluor-3-((4-metylpiperazin-1-yl)metyl)fenyl)ureido)-2-metyl-fenyl)-2-okso-1,2-dihydro-1,6-naftyridin-7-yl) formamid, 3-(1-etyl-3-(4-fluor-2-metyl-5-(3-fenylureido)fenyl)-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)-1,1-dimetylurea, N-(3-(2-klor-4-fluor-5-(3-fenylureido)fenyl)-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)-3-(dimetylamino)azetidin-1-karboksamid, 3-(3-(2-klor-4-fluor-5-(3-fenylureido)fenyl)-1-isopropyl-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)-1,1-dimetylurea, 3-(3-(5-(3-(benzo[b]tiofen-3-yl)ureido)-4-fluor-2-metylfenyl)-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)-1,1-dimetylurea, 3-(3-(2-brom-4-fluor-5-(3-fenylureido)fenyl)-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)-1,1-dimetylurea, 3-(1-etyl-3-(4-fluor-5-(3-(3-fluorfenyl)ureido)-2-metyl-fenyl)-2okso-1,2-dihydro-1,6-naftyridin-7-yl)-1,1-dimetylurea, N-(3-(2-klor-4-fluor-5-(3-(4-fluor-3-(morfolinometyl)fenyl)ureido)fenyl)-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-7-yl) formamid, 3-(3-(5-(3-(3,5-difluorfenyl)ureido)-4-fluor-2-metylfenyl)-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)-1,1-dimetylurea, N-(3-(4-fluor-2-metyl-5-(3-fenylureido)fenyl)-1-isopropyl-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)azetidin-1-karboksamid, N-(1-etyl-3-(4-fluor-2)-metyl-5-(3-fenylureido)fenyl)-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)azetidin-1-karboksamid, 1-(5-(1-etyl-7)-((6-metylpyridin-3-yl)amino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-4-metylfenyl)-3-fenylurea, 3-(3-(2,4-difluor-5)-(3-fenylureido)fenyl)-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)-1,1-dimetylurea, 3-(dimetylamino)-N-(1-etyl-3-(4-fluor-2-metyl-5-(3-fenylureido)fenyl)-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)azetidin-1-karboksamid, 1-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-4-jodfenyl)-3-fenylurea, og 1-(5-(1-etyl-7-((1-metyl-1H-pyrazol-4-yl)amino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-4-metylfenyl)-3-fenylurea.2. Forbindelse for bruk ifølge krav 1, hvor forbindelsen er valgt fra gruppen bestående av: 1-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2,4-difluorfenyl)-3-fenylurea, 1-(benzo[b]tiofen-3-yl)-3-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2,4-difluorfenyl)urea, 1-(5-(7-amino-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-4-klor-2-fluorfenyl)-3-(3-fluorfenyl)urea, 1-(5-(7-amino-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-4-klor-2-fluorfenyl)-3-fenylurea, 1-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-4-metylfenyl)-3-fenylurea, 1-[4-kloro-5-(1-etyl-7-metylamino-2-okso-1,2-dihydro-[1,6]naftyridin-3-yl)-2-fluorfenyl]-3-(3-fluor-fenyl)-urea, 1-(4-brom-5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)-3-fenylurea, 1-(benzo[b]tiofen-3-yl)-3-(4-klor-5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluorfenyl)urea, 1-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-4-metylfenyl)-3-(3-fluorfenyl)urea, 1-(5-(7-amino-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-4-brom-2-fluorfenyl)-3-fenylurea, 1-(benzo[b]tiofen-3-yl)-3-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-4-metylfenyl)urea, 3-(3-(2-klor-4-fluor-5-(3-fenylureido)fenyl)-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)-1,1-dimetylurea, N-(1-etyl-3-(4-fluor-5-(3-(3-fluorfenyl)ureido)-2-metylfenyl)-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)acetamid, N-(1-etyl-3-(4-fluor-2-metyl-5-(3-fenylureido)fenyl)-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)acetamid, og 3-(1-etyl-3-(4-fluor-2-metyl-5)-(3-fenylureido)fenyl)-2-okso-1,2-dihydro-1,6-naftyridin-7-yl)-1,1-dimetylurea.3. Forbindelse for bruk ifølge krav 1, hvor c-KIT, onkogene former derav eller polymorfe derav, kinase-aktivitet derav som forårsaker sykdommen, inneholder en missensemutasjon, innsetting-mutasjon eller en delesjon-mutasjon kodet av eksoner omfattende Ekson 9, Ekson 11, Ekson 13, Ekson 14, Ekson 17 eller Ekson 18, som presenteres enten individuelt eller i kombinasjon.4. Forbindelse for bruk ifølge krav 1, hvor forbindelsen er 1-(4-brom-5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-fenyl)-3-fenylurea.5. Forbindelse for bruk ifølge krav 1, hvor forbindelsen er 1-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-4-metylfenyl)-3-fenylurea.6. Forbindelse for bruk ifølge krav 1, hvor forbindelsen er 1-(benzo[b]tiofen-3-yl)-3-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2-fluor-4-metylfenyl)urea.7. Forbindelse for bruk ifølge krav 1, hvor forbindelsen er 1-(5-(7-amino-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-4-brom-2-fluorfenyl)-3-fenylurea.8. Forbindelse for bruk ifølge krav 1, hvor forbindelsen er 1-(5-(7-amino-1-etyl-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-4-klor-2-fluorfenyl)-3-fenylurea.9. Forbindelse for bruk ifølge krav 4, hvor sykdommen er gastrointestinale stromale tumorer.10. Forbindelse for bruk ifølge krav 4, hvor sykdommen er melanom.11. Forbindelse for bruk ifølge krav 4, hvor sykdommen er mastocytose.12. Forbindelse for bruk ifølge krav 4, hvor sykdommen er akutt myeloid leukemi.13. Forbindelse for bruk ifølge krav 4, hvor sykdommen er mastcelleleukemi.14. En forbindelse som er 1-(3,5-difluorfenyl)-3-(5-(1-etyl-7-(metylamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yl)-2,4-difluorfenyl)urea.15. En farmasøytisk sammensetning omfattende forbindelsen ifølge krav 14 eller et salt derav, sammen med en farmasøytisk akseptabel bærer, hvor bæreren inkluderer et tilsetningsstoff valgt fra gruppen bestående av adjuvanser, eksipienser, diluenter og stabilisatorer.
Hva betyr A1, B, B1, C osv? info
Innehaver i EP:
Deciphera Pharmaceuticals, LLC
643 Massachusetts, Suite 200 Lawrence, Kansas 66044 US
4165 Blackjack Oak Drive Lawrence, KS 66047 US
4708 Muirfield Drive Lawrence, KS 66047 US
1424 N. 960 Road Lawrence, KS 66046 US
Fullmektig i Norge:
ZACCO NORWAY AS
Postboks 488 0213 OSLO NO ( OSLO kommune, Oslo fylke )

Org.nummer: 982702887
Din referanse: V9441NO00
  • Foretaksnavn:
  • Foretaksform:
  • Næring:
  • Forretningsadresse:
     

Kilde: Brønnøysundregistrene
Fullmektig i EP:
McNab, Donald C.
Marks & Clerk LLP 40 Torphichen Street Edinburgh EH3 8JB GB

WO-A1-2008/051757 (B1)

US-A1- 2008 114 006 (B1)

Statushistorie

Liste over statusendringer i sakshistorikk
Hovedstatus Beslutningsdato, detaljstatus
EP patent gjort gjeldende i Norge EP patent besluttet gjeldende i Norge
EP under behandling Forespørsel om å gjøre EP patent gyldig er mottatt

Korrespondanse

Liste over sakshistorikk og korrespondanse
Dato Type korrespondanse Journal beskrivelse
Innkommende EP Publiseringsdokument fra EPO
08-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
07-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
06-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Utgående EP Registreringsbrev (3210) (PTEP3366293)
05-01 Brev UT EP Registreringsbrev (3210) (PTEP3366293)
Innkommende, AR377211601 Korrespondanse (Hovedbrev inn)
04-01 Korrespondanse (Hovedbrev inn) Korrespondanse (Hovedbrev inn)
04-02 Fullmakt Fullmakt
Utgående EP defect letter
03-01 Via Altinn-sending EP defect letter
Innkommende, AR376248427 Søknadsskjema Patent
01-01 Søknadsskjema Patent Søknadsskjema Patent
01-02 EP oversettelse EP krav
Innkommende EP Publiseringsdokument fra EPO
02-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO

Til betaling:

Beskrivelse Forfallsdato Beløp Status
Årsavgift expand_less Ikke betalt
Årsavgift 14. avg. år (EP) 5850,0 Totalbeløp 5850,0   Gå til betaling

Betalingshistorikk:

Liste av betalinger
Beskrivelse / Fakturanummer Betalingsdato Beløp Betaler Status
Årsavgift 13. avg. år (EP) 2024.06.27 5460 COMPUTER PACKAGES INC. Betalt og godkjent
Årsavgift 12. avg. år (EP) 2023.06.28 3850 COMPUTER PACKAGES INC. Betalt og godkjent
Årsavgift 11. avg. år (EP) 2022.06.29 3500 COMPUTER PACKAGES INC. Betalt og godkjent
Årsavgift 10. avg. år (EP) 2021.06.29 3200 COMPUTER PACKAGES INC. Betalt og godkjent
32008368 expand_more 2020.07.06 5500 TANDBERG INNOVATION AS Betalt
Årsavgift 9. avg. år (EP) 2020.05.25 2850 Monica Rebelo Betalt og godkjent
Denne oversikten kan mangle informasjon, spesielt for eldre saker, om tilbakebetaling, internasjonale varemerker og internasjonale design.

Lenker til publikasjoner og Norsk Patenttidende (søkbare tekstdokumenter)

Allment tilgjengelig patentsøknad
Hva betyr A1, B, B1, C osv? info
Kapitler uten data er fjernet. Melding opprettet: 21.05.2025 06:29:13